Immune B-cells that contain the receptor protein CD226 may play a role in the development and clinical manifestations of primary Sjögren’s disease, making CD226 a possible target for future treatments, a study reports. Data indicated that people with Sjögren’s had proportionally more CD226-positive B-cells in their bloodstream than their healthy counterparts. The prevalence of these […] The post B-cells containing CD226 may be Sjögren’s biomarker, therapy target appeared first on S...
